AstriVax is a privately held spin-off company from the KU Leuven, founded in 2022 based on vaccine technology developed at the Rega Institute. AstriVax is building a first in class Plug & Play vaccine platform with a patented DNA based technology that launches self-amplifying live attenuated viruses. The versatile technology of AstriVax can be used to develop a wide range of vaccines to prevent and treat infectious diseases. AstriVax aims to address major challenges in vaccinology by developing novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various viruses and other pathogens. 




Biotechnology

Health Care

Life Sciences

AstriVax

Hanne Callewaert

Isabelle Decoster

Johan Neyts

Wilfried Dalemans

Mathieu Peeters

Greg Fanning

Barbara Freitag

The Research and Development team at AstriVax is dedicated to advancing the company's innovative vaccine platform by conducting cutting-edge research, optimizing vaccine formulations, and ensuring efficacy and safety through preclinical studies. This multidisciplinary team collaborates closely to leverage patented DNA technology, streamline production processes, and ultimately create versatile vaccines aimed at combating infectious diseases with improved accessibility and effectiveness.

Research and Development

Leadership Team

Research and Development

About

Team members

Other teams at AstriVax

Leadership Team